| Literature DB >> 35573865 |
Lingling Li1,2, Ying Yang1,2, Jia Bai1,2, Yangyang Zhang1,2, Hong Yang1,2, Yuqi Zhang1,2, Haihong Lv1.
Abstract
Purpose: It is believed that vascular endothelial dysfunction is involved in the occurrence of cardiovascular disease (CVD), and diabetic peripheral neuropathy (DPN) is associated with flow-mediated dilation (FMD), however, the correlation is still unclear. Aims of the present study is to explore the relationship between DPN parameters and FMD, providing a new approach for the prevention of CVD. Patients andEntities:
Keywords: Toronto clinical scoring system; cardiovascular disease; diabetic peripheral neuropathy; type 2 diabetes; vascular endothelial function
Year: 2022 PMID: 35573865 PMCID: PMC9091688 DOI: 10.2147/DMSO.S352316
Source DB: PubMed Journal: Diabetes Metab Syndr Obes ISSN: 1178-7007 Impact factor: 3.249
Figure 1Flow diagram. The chart shows patient inclusion and exclusion in the study.
Comparison of Clinical and Biochemical Features of Patients with T2DM
| FMD>7% (n, 90) | 4%≤FMD≤7% (n, 91) | FMD<4% (n, 91) | ||
|---|---|---|---|---|
| Age (y) | 53.4±9.6 | 53.4±10.7 | 53.4±8.9 | 0.91 |
| Gender (male/female) | 51/39 | 43/48 | 54/37 | 0.37 |
| BMI (kg/m2) | 22.9±1.8 | 24.8±4.0 | 24.3±3.1 | 0.17 |
| Duration (y) | 9.1±6.5 | 9.3±7.1 | 10.3±7.6 | 0.64 |
| FPG (mmol/L) | 9.5±3.6 | 9.9±4.0 | 9.9±4.2 | 0.76 |
| HbA1c (%) | 8.4±2.1 | 8.5±1.8 | 8.4±1.8 | 0.99 |
| TC (mmol/L) | 3.8±1.0 | 4.2±1.3 | 3.8±1.0 | 0.48 |
| TG (mmol/L) | 1.6±0.8 | 1.6±2.1 | 1.6±1.1 | 0.10 |
| HDL (mmol/L) | 1.0±0.2 | 1.0±0.3 | 0.9±0.2 | 0.18 |
| LDL (mmol/L) | 2.5±0.8 | 2.7±0.9 | 2.5±0.8 | 0.70 |
| SBP (mmHg) | 121.5±24.1 | 129.5±17.9 | 131.7±18.7 | 0.36 |
| DBP (mmHg) | 76.2±8.7 | 80.0±11.3 | 76.7±8.3 | 0.43 |
| HR (bpm) | 83.6±11.6 | 88.6±11.4 | 83.1±12.5 | 0.22 |
| Smoking (%) | 20(22.2%) | 26(28.6%) | 23(25.3%) | 0.16 |
| Drinking (%) | 14(15.6%) | 18(19.8%) | 12(13.2%) | 0.16 |
| 25(OH)D(ng/mL) | 24.6±9.1 | 17.9±6.1 | 17.5±6.8 | 0.11 |
| HCY (µmol/L) | 13.1±3.4 | 13.4±3.6 | 16.8±13.5 | 0.23 |
| baPWV (cm/s) | 1627.1±377.3 | 1623.1±263.7 | 1630.1±595.2 | 0.57 |
| ABI | 1.2±0.1 | 1.2±0.1 | 1.2±0.1 | 0.87 |
Note: Univariate ANOVA and Chi-square test are used in this table.
Abbreviations: FMD, flow-mediated dilation; F, female; M, male; BMI, body mass index; FPG, fasting blood glucose; HbA1C, glycosylated hemoglobin; TC, total cholesterol; TG, triglyceride; HDL, High density lipoprotein; LDL, low density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; HCY, homocysteine; baPWV, brachial ankle pulse wave velocity; ABI, ankle-brachial index.
Proportion of Peripheral Neuropathy Severity in Three Groups
| FMD>7% (n, 90) | 4%≤FMD≤7% (n, 91) | FMD<4% (n, 91) | |
|---|---|---|---|
| No nerve injury (n; %) | 56(62%) | 30(33%) | 3(3%) |
| Mild nerve injury (n; %) | 22(25%) | 24(26%) | 9(10%) |
| Moderate nerve injury (n; %) | 10(11%) | 19(21%) | 16(17%) |
| Severe nerve injury (n; %) | 2(2%) | 18(20%) | 63(70%) |
Notes: Kruskal-Wallis H-test is used in this table X2, 11.114; p, 0.004; the severity of peripheral neuropathy can be considered different among the three groups.
Figure 2Scatter diagram of FMD and TCSS (0–19 points).
Abnormal Ratio of TCSS Indicators of Three Groups
| Total (n, 272) | FMD>7% (n, 90) | 4%≤FMD≤7% (n, 91) | FMD<4% (n, 91) | |||
|---|---|---|---|---|---|---|
| Nerve symptomsa | 44.249 | <0.001 | ||||
| Lower limb pain | 141(52%) | 40(44%) | 50(55%) | 51(56%) | ||
| Numbness | 60(22%) | 5(5%) | 10(11%) | 45(49%) | ||
| Picotement | 44(16%) | 5(5%) | 3(3%) | 36(40%) | ||
| Fatigue | 137(50%) | 45(50%) | 54(59%) | 68(75%) | ||
| Walking imbalance | 33(12%) | 5(5%) | 9(10%) | 19(21%) | ||
| Upper-limb symptoms | 35(13%) | 0 | 9(10%) | 26(29%) | ||
| Sensory examinationsb | 26.758 | 0.003 | ||||
| Acmesthesia | 25(9%) | 5(5%) | 7(8%) | 13(14%) | ||
| Temperature sensation | 198(73%) | 50(55%) | 65(71%) | 83(91%) | ||
| Light touch sensation | 54(20%) | 0 | 18(20%) | 36(40%) | ||
| Vibration sensation | 138(51%) | 10(11%) | 57(63%) | 71(78%) | ||
| Joint-position sensation | 0 | 0 | 0 | 0 | ||
| Nerve reflexesc | 76.631 | <0.001 | ||||
| Ankle reflex | 127(47%) | 9(10%) | 36(40%) | 82(90%) | ||
| Knee reflex | 119(44%) | 9(10%) | 30(33%) | 80(88%) |
Notes: Chi-square test is used in this table TCSS, Toronto clinical scoring system. a is for nerve symptoms; aX2, 44.249; p<0.001; b is for sensory examinations; bX2, 26.758; p, 0.003; c is for nerve reflexes; cX2, 76.631; p<0.001. Nerve symptoms; sensory examinations; and nerve reflexes can be considered different among the three groups.
Correlation Between Components of TCSS and FMD
| FMD (%) | ||
|---|---|---|
| r | ||
| TCSS total points (0–19) | −0.756 | <0.001 |
| Nerve symptoms (0–6) | −0.328 | <0.001 |
| Sensory examination (0–5) | −0.081 | <0.05 |
| Nerve reflexes (0–8) | −0.714 | <0.001 |
Note: Pearson correlation analysis is used in this table.
Abbreviations: TCSS, Toronto clinical scoring system; FMD, flow-mediated dilation.
Comparison of Peripheral Motor Nerve Measurements in Three Groups
| FMD>7% (n, 90) | 4%≤FMD≤7% (n, 91) | FMD<4% (n, 91) | |
|---|---|---|---|
| CV (m/s) | |||
| Median nerve | 51.18±6.56 | 50.23±5.32 | 48.75±5.43ab |
| Ulnar nerve | 50.61±4.85 | 50.16±5.23 | 45.05±5.05ab |
| Common peroneal nerve | 38.43±4.98 | 37.38±7.50 | 35.45±7.90ab |
| Tibial nerve | 38.04±3.51 | 36.98±5.47 | 34.3±5.55ab |
| Amp (mV) | |||
| Median nerve | 6.27±2.30 | 6.16±3.51 | 4.82±1.99ab |
| Ulnar nerve | 7.45±2.49 | 6.93±2.31 | 6.84±2.80ab |
| Common peroneal nerve | 1.19±1.39 | 0.91±1.17 | 0.80±0.87a |
| Tibial nerve | 5.25±2.84 | 5.16±2.50 | 4.40±3.45ab |
| DML (ms) | |||
| Median nerve | 3.08±0.72 | 3.50±0.72 | 4.29±3.07ab |
| Ulnar nerve | 2.53±0.97 | 2.56±0.81 | 2.67±0.52ab |
| Common peroneal nerve | 6.02±3.41 | 6.23±1.97 | 6.62±1.92ab |
| Tibial nerve | 4.43±1.05 | 4.89±2.08 | 5.64±2.27ab |
Notes: Univariate ANOVA and s-N-K test are used in this table Compared with FMD > 7% group; ap<0.05; Compared with 4%≤FMD≤7% group; bp<0.05.
Abbreviations: CV, conduction velocity; Amp, amplitude; DML, distal motor latency.
Correlation Analysis of Motor Nerve CV; Amp; DML and FMD
| FMD>7% (n, 90) | 4%≤FMD≤7% (n, 91) | FMD<4% (n, 91) | ||||
|---|---|---|---|---|---|---|
| CV (m/s) | ||||||
| Median nerve | 0.002 | 0.987 | 0.010 | 0.677 | 0.357 | 0.017 |
| Ulnar nerve | 0.194 | 0.297 | 0.190 | 0.267 | 0.472 | <0.001 |
| Common peroneal nerve | 0.040 | 0.779 | 0.121 | 0.665 | 0.650 | <0.001 |
| Tibial nerve | 0.059 | 0.681 | 0.098 | 0.543 | 0.798 | <0.001 |
| Amp (mV) | ||||||
| Median nerve | 0.005 | 0.972 | 0.111 | 0.767 | 0.340 | 0.028 |
| Ulnar nerve | 0.182 | 0.201 | 0.220 | 0.134 | 0.431 | 0.010 |
| Common peroneal nerve | 0.222 | 0.118 | 0.321 | 0.101 | 0.791 | <0.001 |
| Tibial nerve | 0.121 | 0.397 | 0.226 | 0.267 | 0.790 | <0.001 |
| DML (ms) | ||||||
| Median nerve | −0.274 | 0.072 | −0.254 | 0.102 | −0.359 | 0.017 |
| Ulnar nerve | −0.095 | 0.539 | −0.143 | 0.213 | −0.576 | 0.009 |
| Common peroneal nerve | −0.158 | 0.304 | −0.145 | 0.144 | −0.801 | <0.001 |
| Tibial nerve | −0.220 | 0.151 | −0.221 | 0.151 | −0.767 | <0.001 |
Note: Pearson correlation analysis is used in this table.
Abbreviations: CV, conduction velocity; Amp, amplitude; DML, distal motor latency.
Multiple Linear Regression Analysis of Risk Factors for Endothelial Function Injury in T2DM
| Model1 (R2, 0.262) | Model2 (R2, 0.588) | Model3 (R2, 0.535) | ||||
|---|---|---|---|---|---|---|
| Age | −0.71 | 0.395 | −0.70 | 0.395 | −0.71 | 0.395 |
| Duration | −0.68 | 0.121 | −0.67 | 0.122 | −0.69 | 0.125 |
| FPG | −0.54 | 0.111 | −0.53 | 0.110 | −0.53 | 0.110 |
| HbA1c | −0.55 | 0.159 | −0.55 | 0.156 | −0.56 | 0.159 |
| SBP | −0.60 | 0.002** | −0.60 | 0.002** | −0.60 | 0.002** |
| TG | −0.57 | 0.017* | −0.57 | 0.015* | −0.57 | 0.017* |
| Smoking | −0.015 | 0.056 | −0.015 | 0.056 | −0.014 | 0.055 |
| 25 (OH)D | 0.13 | 0.067 | 0.13 | 0.056 | 0.12 | 0.056 |
| TCSSa | −0.51 | <0.001** | ||||
| CV1b | 0.19 | 0.052 | ||||
| CV2b | 0.24 | 0.067 | ||||
| CV3b | 0.13 | 0.014* | ||||
| CV4b | 0.27 | 0.003** | ||||
| Amp3b | 0.37 | 0.070 | ||||
| Amp4b | 0.04 | 0.070 | ||||
| DML3b | −0.04 | 0.098 | ||||
| DML4b | −0.08 | 0.088 | ||||
Notes: *p<0.05; **p<0.01. Model1: Age; Duration; FPG; HbA1c; SBP and TG are forced to enter the model; and other indicators are entered by stepwise (p<0.05 entered; p>0.1 removed). Model2: Model1 +TCSS score (Age; Duration; FPG; HbA1c; SBP and TG are forced to enter the model; other indicators are entered stepwise; p<0.05 entered; p>0.1 removed) (a is removed from Model3). Model3: CV; Amp and DML of Model1 + median nerve1; ulnar nerve2; common peroneal nerve3 and tibial nerve4 (Age; Duration; FPG; HbA1c; SBP and TG were forced into the model; and other indicators were entered by stepwise. p<0.05 entered; p>0.1 removed) (b is removed from Model2).